[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR070540A1 - Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. - Google Patents

Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.

Info

Publication number
AR070540A1
AR070540A1 ARP090100694A ARP090100694A AR070540A1 AR 070540 A1 AR070540 A1 AR 070540A1 AR P090100694 A ARP090100694 A AR P090100694A AR P090100694 A ARP090100694 A AR P090100694A AR 070540 A1 AR070540 A1 AR 070540A1
Authority
AR
Argentina
Prior art keywords
het
alq
hal
indicates
nhet
Prior art date
Application number
ARP090100694A
Other languages
English (en)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of AR070540A1 publication Critical patent/AR070540A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos derivados de benzonaftiridinilo y análogos de los mismos, y procesos para preparar los mismos. Los compuestos son utiles en el tratamiento de enfermedades sensibles a la inhibicion, regulacion o modulacion de la transduccion de senales de cinasas. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) en donde W se selecciona de Hal, Ar-alq, Het-alq, O, OH, SH, S(O)mZ, S(O)mAr, S(O)mHet, Z, OZ, OAr, OHet, OAlq o NRR'; Q es N o NH para satisfacer la valencia adecuada X se selecciona de N o [N+-O-]; ------- indica un enlace sencillo o doble; R1, R2, R3, R4, R5 y R6 se seleccionan independientemente de hidrogeno, Hal, Z, OZ, OAr, OHet, OH, NRR', Ar, Ar-alq, Het, Het-alq, S(O)mZ, S(O)mAr, S(O)mHet, C(O)mOR, NRC(O)mR', NRSO2R', NRC(O)mNR', (CH2)nOZ o C(O)NRR'; R y R' se seleccionan independientemente de hidrogeno, Z, Ar, Ar-alq, Het, Het-alq, OZ, OAr, S(O)mZ, S(O)mAr o S(O)mHet; Z indica alquilo ramificado o no ramificado C1-10, en la cual 1-7 átomos de H se pueden reemplazar por F, Cl y/o Br, y/o en la cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, N, NH, S, SO, SO2, y/o CH=CH, o alquilo cíclico C3-7; Ar indica fenilo, naftilo o bifenilo, cada uno de los cuales es no sustituido o mono-, di- o trisustituido por Hal, Z, OR, N(R)2, SR, NO2, CN, COOR, CON(R)2, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, Het, O[C(R)2]nN(R), O[C(R)2]nHet, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]pHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]pHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, CHO y/o COZ; Hal indica Cl, Br, I o F; Het indica independientemente un heterociclo mono-, bi- o tricíclico saturado, no saturado o aromático que tiene 1 a 4 átomos de N, O y/o S; que puede ser no sustituido o mono-, di- o trisustituido por Hal, Z, OR, (CH2)pN( R)2, SR, NO2, CN, COOR, CON(R)2, O[C(R)2]nN(R), O[C(R)2]nHet1, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]nHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]nHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, CHO, COZ, =S, =NH, =NZ, oxi (-O-) y/o =O (oxígeno de carbonilo); alq indica alquileno ramificado o no ramificado C1-10, en el cual 1-7 átomos de H se pueden reemplazar por F, Cl, y/o Br, y/o en el cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, S, SO, SO2, NH, NZ, CH=CH y/o C:::C, y que se pueden sustituir por Hal, OR, SR, Ar y/o =O; m es 0, 1 o 2; n es 0, 1, 2, 3, 4, 5 o 6; p es 0, 1, 2, 3 o 4, y en donde al menos uno de R1 a R6 no es H, y un profármaco, derivado, solvato, sal, tautomero y estereoisomero farmacéuticamente aceptable del mismo, incluyendo mezclas de los mismos en todas las proporciones.
ARP090100694A 2008-02-28 2009-02-27 Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. AR070540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6749208P 2008-02-28 2008-02-28

Publications (1)

Publication Number Publication Date
AR070540A1 true AR070540A1 (es) 2010-04-14

Family

ID=40622992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100694A AR070540A1 (es) 2008-02-28 2009-02-27 Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.

Country Status (10)

Country Link
US (1) US8735584B2 (es)
EP (1) EP2254889B1 (es)
JP (1) JP5529761B2 (es)
CN (1) CN101952287B (es)
AR (1) AR070540A1 (es)
AU (1) AU2009219376B2 (es)
CA (1) CA2712990C (es)
ES (1) ES2401550T3 (es)
IL (1) IL207415A (es)
WO (1) WO2009108670A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009333653B2 (en) * 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
EP2485589A4 (en) * 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
ES2590778T3 (es) 2011-02-28 2016-11-23 Calitor Sciences, Llc Compuestos de quinolina sustituida
MY185051A (en) * 2011-03-08 2021-04-30 Basf Se Method for the preparation primary amines by homogeneous catalysed amination of alcohols
CA2844588A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
WO2014022117A1 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
EP2953933A1 (en) * 2013-02-07 2015-12-16 Merck Patent GmbH Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
CN108701171B (zh) * 2015-10-22 2022-06-10 马古苏托科技大学 在通过抑制cyp17a1和cyp19a1治疗癌症中具有应用的药效团、化合物和方法
WO2018172852A1 (en) * 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
KR102229471B1 (ko) * 2018-05-31 2021-03-18 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
AU2019416117B2 (en) 2018-12-28 2024-05-02 Deciphera Pharmaceuticals, Llc CSF1R inhibitors for use in treating cancer
CN116462677A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
AU3652102A (en) 2000-12-01 2002-06-11 Guilford Pharm Inc Compounds and their uses

Also Published As

Publication number Publication date
AU2009219376A1 (en) 2009-09-03
JP5529761B2 (ja) 2014-06-25
CA2712990C (en) 2016-09-27
AU2009219376B2 (en) 2014-09-25
CA2712990A1 (en) 2009-09-03
US20110053906A1 (en) 2011-03-03
IL207415A0 (en) 2010-12-30
EP2254889A1 (en) 2010-12-01
US8735584B2 (en) 2014-05-27
ES2401550T3 (es) 2013-04-22
WO2009108670A1 (en) 2009-09-03
EP2254889B1 (en) 2012-12-19
JP2011513322A (ja) 2011-04-28
CN101952287A (zh) 2011-01-19
CN101952287B (zh) 2013-11-27
IL207415A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
AR070540A1 (es) Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.
AR066543A1 (es) Derivados de piridazinona
AR056327A1 (es) Compuestos de nucleosidos para el tratamiento de infecciones virales
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
AR066892A1 (es) Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit
MX9203122A (es) Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen.
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR068657A1 (es) Derivados de piperidina y piperazina
AR057214A1 (es) Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
AR071208A1 (es) Derivados de piridazinona
SV2010003464A (es) Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas
WO2008080986A1 (en) Furan derivatives, method of synthesis and uses thereof
EA200970582A1 (ru) ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
AR075122A1 (es) Derivados de piridazinona
AR058398A1 (es) Diazepinonas, procesos de obtencion , composiciones farmaceuticas y su uso como inhibidores de quinasas.
AR048573A1 (es) Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
PE20240886A1 (es) Compuestos espirociclicos
AR071217A1 (es) Derivados bencimidazol
MY129329A (en) 6,7-DIHYDRO-5H-PYRAZOLO[1,2-a]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES
US4125547A (en) 12,13(E)-Didehydro-13,14-dihydro-9-deoxy-PGD1 compounds
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
AR045810A1 (es) 6-[fenil (sustituidas) ] triazolopirimidinas como agentes anticancerosos

Legal Events

Date Code Title Description
FG Grant, registration